-
Wang J, Cho NL, Zauber AG, Hsu M, Dawson D, Srivastava A, Mitchell-Richards KA, Markowitz SD, Bertagnolli MM. Chemopreventive efficacy of the cyclooxygenase-2 (Cox-2) inhibitor, celecoxib, is predicted by adenoma expression of Cox-2 and 15-PGDH. Cancer Epidemiol Biomarkers Prev. 2018 May 16. PMID: 29769213.
-
Rosenberg L, Yoon CH, Sharma G, Bertagnolli MM, Cho NL. Sorafenib inhibits proliferation and invasion in desmoid-derived cells by targeting Ras/MEK/ERK and PI3K/Akt/mTOR pathways. Carcinogenesis. 2018 May 03; 39(5):681-688. PMID: 29538717.
-
Fairweather M, Cavnar MJ, Li GZ, Bertagnolli MM, DeMatteo RP, Raut CP. Prediction of morbidity following cytoreductive surgery for metastatic gastrointestinal stromal tumour in patients on tyrosine kinase inhibitor therapy. Br J Surg. 2018 May; 105(6):743-750. PMID: 29579329.
-
Erstad DJ, Ready J, Abraham J, Ferrone ML, Bertagnolli MM, Baldini EH, Raut CP. Amputation for Extremity Sarcoma: Contemporary Indications and Outcomes. Ann Surg Oncol. 2018 Feb; 25(2):394-403. PMID: 29168103.
-
Fairweather M, Wang J, Jo VY, Baldini EH, Bertagnolli MM, Raut CP. Surgical Management of Primary Retroperitoneal Sarcomas: Rationale for Selective Organ Resection. Ann Surg Oncol. 2018 Jan; 25(1):98-106. PMID: 29067605.
-
Kuba MG, Lester SC, Giess CS, Bertagnolli MM, Wieczorek TJ, Brock JE. Fibromatosis of the Breast: Diagnostic Accuracy of Core Needle Biopsy. Am J Clin Pathol. 2017 Sep 01; 148(3):243-250. PMID: 28821190.
-
Bertagnolli MM, O'Dwyer PJ. Robert L. Comis: In Memoriam. Oncologist. 2017 Aug; 22(8):1012-1013. PMID: 28710343.
-
Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB, Mulkerin DL, Mayer RJ, Blanke C. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2017 06 20; 317(23):2392-2401. PMID: 28632865.
-
Fuchs MA, Yuan C, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Innocenti F, Warren RS, Bertagnolli MM, Ogino S, Giovannucci EL, Horvath E, Meyerhardt JA, Ng K. Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance). Ann Oncol. 2017 Jun 01; 28(6):1359-1367. PMID: 28327908.
-
Wang X, Häring MF, Rathjen T, Lockhart SM, Sørensen D, Ussar S, Rasmussen LM, Bertagnolli MM, Kahn CR, Rask-Madsen C. Insulin resistance in vascular endothelial cells promotes intestinal tumour formation. Oncogene. 2017 08 31; 36(35):4987-4996. PMID: 28459466.
-
Fairweather M, Balachandran VP, Li GZ, Bertagnolli MM, Antonescu C, Tap W, Singer S, DeMatteo RP, Raut CP. Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors: A 2-institutional Analysis. Ann Surg. 2017 Apr 26. PMID: 28448384.
-
Li GZ, Fairweather M, Wang J, Orgill DP, Bertagnolli MM, Raut CP. Cutaneous Radiation-associated Breast Angiosarcoma: Radicality of Surgery Impacts Survival. Ann Surg. 2017 04; 265(4):814-820. PMID: 28267696.
-
Bertagnolli MM, Sartor O, Chabner BA, Rothenberg ML, Khozin S, Hugh-Jones C, Reese DM, Murphy MJ. Advantages of a Truly Open-Access Data-Sharing Model. N Engl J Med. 2017 Mar 23; 376(12):1178-1181. PMID: 28328337.
-
Fairweather M, Wang J, Jo VY, Baldini EH, Bertagnolli MM, Raut CP. Incidence and Adverse Prognostic Implications of Histopathologic Organ Invasion in Primary Retroperitoneal Sarcoma. J Am Coll Surg. 2017 May; 224(5):876-883. PMID: 28147251.
-
Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F. Reply to L. Casadaban et al. J Clin Oncol. 2017 Apr 20; 35(12):1373-1374. PMID: 28113023.
-
Niedzwiecki D, Hasson RM, Lenz HJ, Ye C, Redston M, Ogino S, Fuchs CS, Compton CC, Mayer RJ, Goldberg RM, Colacchio TA, Saltz LB, Warren RS, Bertagnolli MM. A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803. Oncologist. 2017 01; 22(1):107-114. PMID: 27821793.
-
Izar B, Joyce CE, Goff S, Cho NL, Shah PM, Sharma G, Li J, Ibrahim N, Gold J, Hodi FS, Garraway LA, Novina CD, Bertagnolli MM, Yoon CH. Bidirectional cross talk between patient-derived melanoma and cancer-associated fibroblasts promotes invasion and proliferation. Pigment Cell Melanoma Res. 2016 Nov; 29(6):656-668. PMID: 27482935.
-
Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F. Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance). J Clin Oncol. 2016 Sep 01; 34(25):3047-53. PMID: 27432924; PMCID: PMC5012711 [Available on 09/01/17].
-
Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183. PMID: 27479034.
-
Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586. PMID: 27070704.
-
Tirosh I, Izar B, Prakadan SM, Wadsworth MH, Treacy D, Trombetta JJ, Rotem A, Rodman C, Lian C, Murphy G, Fallahi-Sichani M, Dutton-Regester K, Lin JR, Cohen O, Shah P, Lu D, Genshaft AS, Hughes TK, Ziegler CG, Kazer SW, Gaillard A, Kolb KE, Villani AC, Johannessen CM, Andreev AY, Van Allen EM, Bertagnolli M, Sorger PK, Sullivan RJ, Flaherty KT, Frederick DT, Jané-Valbuena J, Yoon CH, Rozenblatt-Rosen O, Shalek AK, Regev A, Garraway LA. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016 Apr 08; 352(6282):189-96. PMID: 27124452; PMCID: PMC4944528.
-
Montazeri Z, Theodoratou E, Nyiraneza C, Timofeeva M, Chen W, Svinti V, Sivakumaran S, Gresham G, Cubitt L, Carvajal-Carmona L, Bertagnolli MM, Zauber AG, Tomlinson I, Farrington SM, Dunlop MG, Campbell H, Little J. Systematic meta-analyses and field synopsis of genetic association studies in colorectal adenomas. Int J Epidemiol. 2016 Feb; 45(1):186-205. PMID: 26451011.
-
Fairweather M, Jajoo K, Sainani N, Bertagnolli MM, Wang J. Accuracy of EUS and CT imaging in preoperative gastric cancer staging. J Surg Oncol. 2015 Jun; 111(8):1016-20. PMID: 25872753.
-
Wang J, Sun Y, Bertagnolli MM. Comparison of gastric cancer survival between Caucasian and Asian patients treated in the United States: results from the Surveillance Epidemiology and End Results (SEER) database. Ann Surg Oncol. 2015 Sep; 22(9):2965-71. PMID: 25631065.
-
Briggs A, Rosenberg L, Buie JD, Rizvi H, Bertagnolli MM, Cho NL. Antitumor effects of hyaluronan inhibition in desmoid tumors. Carcinogenesis. 2015 Feb; 36(2):272-9. PMID: 25556151.
-
Fairweather M, Heit YI, Buie J, Rosenberg LM, Briggs A, Orgill DP, Bertagnolli MM. Celecoxib inhibits early cutaneous wound healing. J Surg Res. 2015 Apr; 194(2):717-24. PMID: 25588948.
-
Fairweather M, Wang J, Devlin PM, Hansen J, Baldini EH, Ready JE, Sugarbaker DJ, Bertagnolli MM, Raut CP. Safety and efficacy of radiation dose delivered via iodine-125 brachytherapy mesh implantation for deep cavity sarcomas. Ann Surg Oncol. 2015 May; 22(5):1455-63. PMID: 25341749.
-
Bertagnolli MM, Canetta R, Nass SJ. Expanding public-private collaborations to enhance cancer drug development: a report of the Institute of Medicine's workshop series, "Implementing a National Cancer Clinical Trials System for the 21st Century". Oncologist. 2014 Nov; 19(11):1179-85. PMID: 25326161; PMCID: PMC4221375.
-
Pavelitz T, Renfro L, Foster NR, Caracol A, Welsch P, Lao VV, Grady WB, Niedzwiecki D, Saltz LB, Bertagnolli MM, Goldberg RM, Rabinovitch PS, Emond M, Monnat RJ, Maizels N. MRE11-deficiency associated with improved long-term disease free survival and overall survival in a subset of stage III colon cancer patients in randomized CALGB 89803 trial. PLoS One. 2014; 9(10):e108483. PMID: 25310185; PMCID: PMC4195600.
-
Niedzwiecki D, Lenz HJ, Innocenti F, Mahoney MR, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Mayer RJ, Schilsky RL, Bertagnolli MM, Blanke CD. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol. 2014 Jun 20; 32(18_suppl):LBA3. PMID: 28141983.
-
Mendelsohn J, Bertagnolli MM. The 2010 Institute of Medicine consensus statement "A national clinical trials network for the 21st century": progress and challenges. Semin Oncol. 2014 Aug; 41(4):435-436. PMID: 25173135.
-
Shiovitz S, Bertagnolli MM, Renfro LA, Nam E, Foster NR, Dzieciatkowski S, Luo Y, Lao VV, Monnat RJ, Emond MJ, Maizels N, Niedzwiecki D, Goldberg RM, Saltz LB, Venook A, Warren RS, Grady WM. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. Gastroenterology. 2014 Sep; 147(3):637-45. PMID: 24859205.
-
Fiore M, Coppola S, Cannell AJ, Colombo C, Bertagnolli MM, George S, Le Cesne A, Gladdy RA, Casali PG, Swallow CJ, Gronchi A, Bonvalot S, Raut CP. Desmoid-type fibromatosis and pregnancy: a multi-institutional analysis of recurrence and obstetric risk. Ann Surg. 2014 May; 259(5):973-8. PMID: 24477160.
-
Serrano C, Wang Y, Mariño-EnrÃquez A, Lee JC, Ravegnini G, Morgan JA, Bertagnolli MM, Beadling C, Demetri GD, Corless CL, Heinrich MC, Fletcher JA. KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation. J Clin Oncol. 2015 Aug 01; 33(22):e93-6. PMID: 24687822; PMCID: PMC4559610.
-
Hasson RM, Briggs A, Rizvi H, Carothers AM, Davids JS, Bertagnolli MM, Cho NL. Lack of anti-tumor activity with the ß-catenin expression inhibitor EZN-3892 in the C57BL/6J Min/+ model of intestinal carcinogenesis. Biochem Biophys Res Commun. 2014 Feb 14; 444(3):283-9. PMID: 24486542.
-
Ogino S, Liao X, Imamura Y, Yamauchi M, McCleary NJ, Ng K, Niedzwiecki D, Saltz LB, Mayer RJ, Whittom R, Hantel A, Benson AB, Mowat RB, Spiegelman D, Goldberg RM, Bertagnolli MM, Meyerhardt JA, Fuchs CS. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst. 2013 Dec 04; 105(23):1789-98. PMID: 24231454; PMCID: PMC3848984.
-
Keung EZ, Hornick JL, Bertagnolli MM, Baldini EH, Raut CP. Predictors of outcomes in patients with primary retroperitoneal dedifferentiated liposarcoma undergoing surgery. J Am Coll Surg. 2014 Feb; 218(2):206-17. PMID: 24315890.
-
Hasson RM, Briggs A, Carothers AM, Davids JS, Wang J, Javid SH, Cho NL, Bertagnolli MM. Estrogen receptor a or ß loss in the colon of Min/+ mice promotes crypt expansion and impairs TGFß and HNF3ß signaling. Carcinogenesis. 2014 Jan; 35(1):96-102. PMID: 24104551; PMCID: PMC3871939.
-
Nixon AB, Pang H, Starr MD, Friedman PN, Bertagnolli MM, Kindler HL, Goldberg RM, Venook AP, Hurwitz HI. Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res. 2013 Dec 15; 19(24):6957-66. PMID: 24097873; PMCID: PMC4219241.
-
Wang J, Carvajal-Carmona LG, Chu JH, Zauber AG, Kubo M, Matsuda K, Dunlop M, Houlston RS, Sieber O, Lipton L, Gibbs P, Martin NG, Montgomery GW, Young J, Baird PN, Ratain MJ, Nakamura Y, Weiss ST, Tomlinson I, Bertagnolli MM. Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study. Clin Cancer Res. 2013 Dec 01; 19(23):6430-7. PMID: 24084763.
-
Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Warren RS, Bertagnolli MM, Nelson GD, Goldberg RM, Sargent DJ, Alberts SR. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol. 2013 Oct 10; 31(29):3664-72. PMID: 24019539; PMCID: PMC3789216.
-
Warren RS, Atreya CE, Niedzwiecki D, Weinberg VK, Donner DB, Mayer RJ, Goldberg RM, Compton CC, Zuraek MB, Ye C, Saltz LB, Bertagnolli MM. Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. Clin Cancer Res. 2013 Oct 15; 19(20):5777-87. PMID: 23983256; PMCID: PMC4122229.
-
Venook AP, Niedzwiecki D, Lopatin M, Ye X, Lee M, Friedman PN, Frankel W, Clark-Langone K, Millward C, Shak S, Goldberg RM, Mahmoud NN, Warren RS, Schilsky RL, Bertagnolli MM. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol. 2013 May 10; 31(14):1775-81. PMID: 23530100; PMCID: PMC3641698.
-
McBride SM, Raut CP, Lapidus M, Devlin PM, Marcus KJ, Bertagnolli M, George S, Baldini EH. Locoregional recurrence after preoperative radiation therapy for retroperitoneal sarcoma: adverse impact of multifocal disease and potential implications of dose escalation. Ann Surg Oncol. 2013 Jul; 20(7):2140-7. PMID: 23392853.
-
Baldini EH, Lapidus MR, Wang Q, Manola J, Orgill DP, Pomahac B, Marcus KJ, Bertagnolli MM, Devlin PM, George S, Abraham J, Ferrone ML, Ready JE, Raut CP. Predictors for major wound complications following preoperative radiotherapy and surgery for soft-tissue sarcoma of the extremities and trunk: importance of tumor proximity to skin surface. Ann Surg Oncol. 2013 May; 20(5):1494-9. PMID: 23242820.
-
Carvajal-Carmona LG, Zauber AG, Jones AM, Howarth K, Wang J, Cheng T, Riddell R, Lanas A, Morton D, Bertagnolli MM, Tomlinson I. Much of the genetic risk of colorectal cancer is likely to be mediated through susceptibility to adenomas. Gastroenterology. 2013 Jan; 144(1):53-5. PMID: 22999960.
-
Gong L, Thorn CF, Bertagnolli MM, Grosser T, Altman RB, Klein TE. Celecoxib pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012 Apr; 22(4):310-8. PMID: 22336956; PMCID: PMC3303994.
-
Peppercorn J, Shapira I, Deshields T, Kroetz D, Friedman P, Spears P, Collyar DE, Shulman LN, Dressler L, Bertagnolli MM. Ethical aspects of participation in the database of genotypes and phenotypes of the National Center for Biotechnology Information: the Cancer and Leukemia Group B Experience. Cancer. 2012 Oct 15; 118(20):5060-8. PMID: 22415847.
-
Arber N, Lieberman D, Wang TC, Zhang R, Sands GH, Bertagnolli MM, Hawk ET, Eagle C, Coindreau J, Zauber A, Lanas A, Levin B. The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo. Clin Ther. 2012 Mar; 34(3):569-79. PMID: 22386831.
-
Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson AB, Spiegelman D, Goldberg RM, Bertagnolli MM, Fuchs CS. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res. 2012 Feb 01; 18(3):890-900. PMID: 22147942; PMCID: PMC3271172.
-
Carothers AM, Rizvi H, Hasson RM, Heit YI, Davids JS, Bertagnolli MM, Cho NL. Mesenchymal stromal cell mutations and wound healing contribute to the etiology of desmoid tumors. Cancer Res. 2012 Jan 01; 72(1):346-55. PMID: 22094874; PMCID: PMC3251735.
-
Chan AT, Hsu M, Zauber AG, Hawk ET, Bertagnolli MM. The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma. Cancer Prev Res (Phila). 2012 Jan; 5(1):61-72. PMID: 22030088; PMCID: PMC3252487.
-
Ng K, Ogino S, Meyerhardt JA, Chan JA, Chan AT, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Benson AB, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Bertagnolli MM, Venook AP, Fuchs CS. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst. 2011 Oct 19; 103(20):1540-51. PMID: 21849660; PMCID: PMC3196479.
-
Chan AT, Sima CS, Zauber AG, Ridker PM, Hawk ET, Bertagnolli MM. C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. Cancer Prev Res (Phila). 2011 Aug; 4(8):1172-80. PMID: 21816845; PMCID: PMC3151679.
-
Bertagnolli MM, Redston M, Compton CC, Niedzwiecki D, Mayer RJ, Goldberg RM, Colacchio TA, Saltz LB, Warren RS. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. J Clin Oncol. 2011 Aug 10; 29(23):3153-62. PMID: 21747089; PMCID: PMC3157981.
-
Niedzwiecki D, Bertagnolli MM, Warren RS, Compton CC, Kemeny NE, Benson AB, Eckhardt SG, Alberts S, Porjosh GN, Kerr DJ, Fields A, Rougier P, Pipas JM, Schwartz JH, Atkins J, O'Rourke M, Perry MC, Goldberg RM, Mayer RJ, Colacchio TA. Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. J Clin Oncol. 2011 Aug 10; 29(23):3146-52. PMID: 21747085; PMCID: PMC3157980.
-
Jones AM, Beggs AD, Carvajal-Carmona L, Farrington S, Tenesa A, Walker M, Howarth K, Ballereau S, Hodgson SV, Zauber A, Bertagnolli M, Midgley R, Campbell H, Kerr D, Dunlop MG, Tomlinson IP. TERC polymorphisms are associated both with susceptibility to colorectal cancer and with longer telomeres. Gut. 2012 Feb; 61(2):248-54. PMID: 21708826.
-
Venook AP, Niedzwiecki D, Lopatin M, Lee M, Friedman PN, Frankel W, Clark-Langone K, Yoshizawa C, Millward C, Shak S, Goldberg RM, Mahmoud NN, Schilsky RL, Bertagnolli MM. Validation of a 12-gene colon cancer recurrence score (RS) in patients (pts) with stage II colon cancer (CC) from CALGB 9581. J Clin Oncol. 2011 May 20; 29(15_suppl):3518. PMID: 28020339.
-
Nixon AB, Pang H, Starr M, Hollis D, Friedman PN, Bertagnolli MM, Kindler HL, Goldberg RM, Venook AP, Hurwitz H. Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: Results from CALGB 80303. J Clin Oncol. 2011 May 20; 29(15_suppl):10508. PMID: 28022380.
-
Cho NL, Carothers AM, Rizvi H, Hasson RM, Redston M, Bertagnolli MM. Immunohistochemical and molecular analysis of tyrosine kinase activity in desmoid tumors. J Surg Res. 2012 Apr; 173(2):320-6. PMID: 21195420.
-
Goldberg RM, Bertagnolli MM. VICTOR spoiled? J Clin Oncol. 2010 Oct 20; 28(30):4546-8. PMID: 20837951.
-
Carothers AM, Davids JS, Damas BC, Bertagnolli MM. Persistent cyclooxygenase-2 inhibition downregulates NF-{kappa}B, resulting in chronic intestinal inflammation in the min/+ mouse model of colon tumorigenesis. Cancer Res. 2010 Jun 01; 70(11):4433-42. PMID: 20484034; PMCID: PMC3242378.
-
Peppercorn J, Shapira I, Collyar D, Deshields T, Lin N, Krop I, Grunwald H, Friedman P, Partridge AH, Schilsky RL, Bertagnolli MM. Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology. J Clin Oncol. 2010 May 20; 28(15):2635-40. PMID: 20406927.
-
Bertagnolli MM, Hsu M, Hawk ET, Eagle CJ, Zauber AG. Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila). 2010 May; 3(5):588-96. PMID: 20403998; PMCID: PMC2990920.
-
Kouzminova N, Lu T, Lin AY. Molecular basis of colorectal cancer. N Engl J Med. 2010 Apr 01; 362(13):1245-6; author reply 1246-7. PMID: 20357292.
-
Tejpar S, Bertagnolli M, Bosman F, Lenz HJ, Garraway L, Waldman F, Warren R, Bild A, Collins-Brennan D, Hahn H, Harkin DP, Kennedy R, Ilyas M, Morreau H, Proutski V, Swanton C, Tomlinson I, Delorenzi M, Fiocca R, Van Cutsem E, Roth A. Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist. 2010; 15(4):390-404. PMID: 20350999; PMCID: PMC3227961.
-
Davids JS, Carothers AM, Damas BC, Bertagnolli MM. Chronic cyclooxygenase-2 inhibition promotes myofibroblast-associated intestinal fibrosis. Cancer Prev Res (Phila). 2010 Mar; 3(3):348-58. PMID: 20179298; PMCID: PMC2833233.
-
Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med. 2009 Dec 17; 361(25):2449-60. PMID: 20018966; PMCID: PMC2843693.
-
Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson AB, Goldberg RM, Bertagnolli MM, Fuchs CS. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res. 2009 Dec 01; 15(23):7322-9. PMID: 19934290; PMCID: PMC2787689.
-
Raut CP, Wang Q, Manola J, Morgan JA, George S, Wagner AJ, Butrynski JE, Fletcher CD, Demetri GD, Bertagnolli MM. Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate. Ann Surg Oncol. 2010 Feb; 17(2):407-15. PMID: 19898902.
-
Bertagnolli MM. The forest and the trees: pathways and proteins as colorectal cancer biomarkers. J Clin Oncol. 2009 Dec 10; 27(35):5866-7. PMID: 19884524.
-
Mery CM, George S, Bertagnolli MM, Raut CP. Secondary sarcomas after radiotherapy for breast cancer: sustained risk and poor survival. Cancer. 2009 Sep 15; 115(18):4055-63. PMID: 19526590.
-
Mani M, Carrasco DE, Zhang Y, Takada K, Gatt ME, Dutta-Simmons J, Ikeda H, Diaz-Griffero F, Pena-Cruz V, Bertagnolli M, Myeroff LL, Markowitz SD, Anderson KC, Carrasco DR. BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. Cancer Res. 2009 Oct 01; 69(19):7577-86. PMID: 19738061; PMCID: PMC4321734.
-
Raut CP, Nucci MR, Wang Q, Manola J, Bertagnolli MM, Demetri GD, Morgan JA, Muto MG, Fletcher CD, George S. Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma. Eur J Cancer. 2009 Nov; 45(16):2818-24. PMID: 19647426.
-
Yan M, Myung SJ, Fink SP, Lawrence E, Lutterbaugh J, Yang P, Zhou X, Liu D, Rerko RM, Willis J, Dawson D, Tai HH, Barnholtz-Sloan JS, Newman RA, Bertagnolli MM, Markowitz SD. 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc Natl Acad Sci U S A. 2009 Jun 09; 106(23):9409-13. PMID: 19470469; PMCID: PMC2695050.
-
Fuchs C, Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Bertagnolli MM. KRAS mutation, cancer recurrence, and patient survival in stage III colon cancer: Findings from CALGB 89803. J Clin Oncol. 2009 May 20; 27(15_suppl):4037. PMID: 27961543.
-
Bertagnolli MM, Niedzwiecki D, Hall M, Jewell SD, Mayer RJ, Goldberg RM, Colacchio TA, Warren RS, Redston M. Presence of 18q loss of heterozygosity (LOH) and disease-free and overall survival in stage II colon cancer: CALGB Protocol 9581. J Clin Oncol. 2009 May 20; 27(15_suppl):4012. PMID: 27961506.
-
Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim K, Tang J, Rosenstein RB, Umar A, Bagheri D, Collins NT, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Hawk ET. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila). 2009 Apr; 2(4):310-21. PMID: 19336730; PMCID: PMC2976587.
-
Bertagnolli MM, Warren RS, Niedzwiecki D, Mueller E, Compton CC, Redston M, Hall M, Hahn HP, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, Loda M. p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803. Clin Cancer Res. 2009 Mar 15; 15(6):2116-22. PMID: 19276255; PMCID: PMC3059545.
-
Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, Damas B, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, Warren RS, Redston M. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol. 2009 Apr 10; 27(11):1814-21. PMID: 19273709; PMCID: PMC2668707.
-
Bertagnolli MM, Zauber AG, Solomon S. Prostaglandin inhibition and cardiovascular risk: maybe timing really is everything. Cancer Prev Res (Phila). 2009 Mar; 2(3):195-6. PMID: 19258547.
-
Chan AT, Zauber AG, Hsu M, Breazna A, Hunter DJ, Rosenstein RB, Eagle CJ, Hawk ET, Bertagnolli MM. Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology. 2009 Jun; 136(7):2127-2136.e1. PMID: 19233181; PMCID: PMC2693443.
-
Lin CI, Whang EE, Abramson MA, Donner DB, Bertagnolli MM, Moore FD, Ruan DT. Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells. Biochem Biophys Res Commun. 2009 Feb 06; 379(2):626-31. PMID: 19124005.
-
Raut CP, Bertagnolli MM. Controversies in the surgical management of GIST in the era of imatinib. Oncology (Williston Park). 2009 Jan; 23(1):69, 74-6. PMID: 19283924.
-
Bertagnolli MM. Doing our best: surgery for rectal cancer. Gut. 2008 Dec; 57(12):1643-5. PMID: 19022921.
-
Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, Ryan CW, von Mehren M, Blanke CD, Rankin C, Benjamin RS, Bramwell VH, Demetri GD, Bertagnolli MM, Fletcher JA. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 2008 Nov 20; 26(33):5360-7. PMID: 18955451; PMCID: PMC2651078.
-
Wirth LJ, Krane JF, Li Y, Othus M, Moran AE, Dorfman DM, Norris CM, Goguen L, Posner MR, Haddad RI, Bertagnolli MM. A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions. Cancer Prev Res (Phila). 2008 Oct; 1(5):339-48. PMID: 19138978.
-
Bertagnolli MM, Morgan JA, Fletcher CD, Raut CP, Dileo P, Gill RR, Demetri GD, George S. Multimodality treatment of mesenteric desmoid tumours. Eur J Cancer. 2008 Nov; 44(16):2404-10. PMID: 18706807.
-
Chan JA, Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Thomas J, Schaefer P, Whittom R, Hantel A, Goldberg RM, Warren RS, Bertagnolli M, Fuchs CS. Association of family history with cancer recurrence and survival among patients with stage III colon cancer. JAMA. 2008 Jun 04; 299(21):2515-23. PMID: 18523220; PMCID: PMC3616330.
-
Cho NL, Redston M, Zauber AG, Carothers AM, Hornick J, Wilton A, Sontag S, Nishioka N, Giardiello FM, Saltzman JR, Gostout C, Eagle CJ, Hawk ET, Bertagnolli MM. Aberrant crypt foci in the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila). 2008 Jun; 1(1):21-31. PMID: 19138933.
-
Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL, Goss PE, Lance P, Obara S, Chew EY, Kim J, Arndt G, Hawk E. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation. 2008 Apr 22; 117(16):2104-13. PMID: 18378608.
-
Ito H, Hornick JL, Bertagnolli MM, George S, Morgan JA, Baldini EH, Wagner AJ, Demetri GD, Raut CP. Leiomyosarcoma of the inferior vena cava: survival after aggressive management. Ann Surg Oncol. 2007 Dec; 14(12):3534-41. PMID: 17896156.
-
Bertagnolli MM. Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: two steps forward, one step back. Lancet Oncol. 2007 May; 8(5):439-43. PMID: 17466901.
-
Cho NL, Javid SH, Carothers AM, Redston M, Bertagnolli MM. Estrogen receptors alpha and beta are inhibitory modifiers of Apc-dependent tumorigenesis in the proximal colon of Min/+ mice. Cancer Res. 2007 Mar 01; 67(5):2366-72. PMID: 17332369.
-
Bertagnolli MM. Cox-2 and cancer chemoprevention: picking up the pieces. Recent Results Cancer Res. 2007; 174:73-8. PMID: 17302187.
-
Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, Niedzwiecki D, Compton C, Mayer RJ, Goldberg R, Bertagnolli MM, Boland CR. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology. 2007 Jan; 132(1):127-38. PMID: 17087942.
-
Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG, Bertagnolli MM, Arber N, Wittes J. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation. 2006 Sep 05; 114(10):1028-35. PMID: 16943394.
-
Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006 Aug 31; 355(9):873-84. PMID: 16943400.
-
Raut CP, Van Den Abbeele A, Ramaiya N, Morgan JA, George S, Quigley MT, Dollard AM, Bertagnolli MM, Baum C, Demetri GD. Patterns of PET response after long-term sunitinib therapy in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumors (GIST). J Clin Oncol. 2006 Jun 20; 24(18_suppl):9547. PMID: 27952946.
-
Bertagnolli MM, Compton CC, Niedzwiecki D, Warren RS, Jewell S, Bailey GP, Mayer RJ, Goldberg R, Saltz L, Redston M. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, 5-fluorouracil and leucovorin in stage III colon cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):10003. PMID: 27955350.
-
Carothers AM, Moran AE, Cho NL, Redston M, Bertagnolli MM. Changes in antitumor response in C57BL/6J-Min/+ mice during long-term administration of a selective cyclooxygenase-2 inhibitor. Cancer Res. 2006 Jun 15; 66(12):6432-8. PMID: 16778222.
-
Goldberg RM, Niedzwiecki D, Bertagnolli M, Blackstock AW, Tepper JE, Mayer RJ. Cancer and leukemia group B gastrointestinal cancer committee. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3589s-95s. PMID: 16740790.
-
Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, Fletcher CD, Demetri GD, Bertagnolli MM. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol. 2006 May 20; 24(15):2325-31. PMID: 16710031.
-
Carothers AM, Javid SH, Moran AE, Hunt DH, Redston M, Bertagnolli MM. Deficient E-cadherin adhesion in C57BL/6J-Min/+ mice is associated with increased tyrosine kinase activity and RhoA-dependent actomyosin contractility. Exp Cell Res. 2006 Feb 15; 312(4):387-400. PMID: 16368433.
-
Redston M, Compton CC, Miedema BW, Niedzwiecki D, Dowell JM, Jewell SD, Fleshman JM, Bem J, Mayer RJ, Bertagnolli MM. Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: results of Cancer and Leukemia Group B Trial 80001. J Clin Oncol. 2006 Feb 20; 24(6):878-83. PMID: 16418493.
-
Bertagnolli MM. Radioimmunotherapy for colorectal cancer. Clin Cancer Res. 2005 Jul 01; 11(13):4637-8. PMID: 16000553.
-
Bauer S, Hubert C, Heinrich MC, Cohen P, Bertagnolli M, Demetri GD, Fletcher J. KIT hyperactivation in imatinib-resistant GIST: Implications for salvage therapies. J Clin Oncol. 2005 Jun; 23(16_suppl):9034. PMID: 27945576.
-
Wirth LJ, Moran AE, Krane JF, Weeks L, Norris CM, Goguen LA, Sullivan CA, Haddad RI, Posner MR, Bertagnolli MM. Pilot study of celecoxib in oral premalignant lesions (OPLs): Preliminary results. J Clin Oncol. 2005 Jun; 23(16_suppl):1025. PMID: 27944947.
-
Heinrich MC, Shoemaker JS, Corless CL, Hollis D, Demetri GD, Bertagnolli MM, Fletcher JA. Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT+). J Clin Oncol. 2005 Jun; 23(16_suppl):7. PMID: 27946616.
-
Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005 Mar 17; 352(11):1071-80. PMID: 15713944.
-
Moran AE, Carothers AM, Weyant MJ, Redston M, Bertagnolli MM. Carnosol inhibits beta-catenin tyrosine phosphorylation and prevents adenoma formation in the C57BL/6J/Min/+ (Min/+) mouse. Cancer Res. 2005 Feb 01; 65(3):1097-104. PMID: 15705912.
-
Bertagnolli MM. Surgical prevention of cancer. J Clin Oncol. 2005 Jan 10; 23(2):324-32. PMID: 15637395.
-
Goel A, Arnold CN, Tassone P, Chang DK, Niedzwiecki D, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR. Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers. Int J Cancer. 2004 Dec 10; 112(5):754-9. PMID: 15386381.
-
Javid SH, Moran AE, Carothers AM, Redston M, Bertagnolli MM. Modulation of tumor formation and intestinal cell migration by estrogens in the Apc(Min/+) mouse model of colorectal cancer. Carcinogenesis. 2005 Mar; 26(3):587-95. PMID: 15579483.
-
Arnold CN, Goel A, Niedzwiecki D, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR. APC promoter hypermethylation contributes to the loss of APC expression in colorectal cancers with allelic loss on 5q. Cancer Biol Ther. 2004 Oct; 3(10):960-4. PMID: 15326380.
-
Bertagnolli M, Miedema B, Redston M, Dowell J, Niedzwiecki D, Fleshman J, Bem J, Mayer R, Zinner M, Compton C. Sentinel node staging of resectable colon cancer: results of a multicenter study. Ann Surg. 2004 Oct; 240(4):624-8; discussion 628-30. PMID: 15383790; PMCID: PMC1356464.
-
Moran AE, Hunt DH, Javid SH, Redston M, Carothers AM, Bertagnolli MM. Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+ mice. J Biol Chem. 2004 Oct 08; 279(41):43261-72. PMID: 15294912.
-
Bertagnolli MM, Redston M, Miedema B, Dowell J, Niedzwiecki D, Mayer R, Fleshman J, Bem J, Compton C. Sentinel node staging of resectable colon cancer: Results of CALGB 80001. J Clin Oncol. 2004 Jul 15; 22(14_suppl):3506. PMID: 28016487.
-
Kulke MH, Odze RD, Mueller JD, Wang H, Redston M, Bertagnolli MM. Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer. J Thorac Cardiovasc Surg. 2004 Jun; 127(6):1579-86. PMID: 15173710.
-
Goel A, Arnold CN, Niedzwiecki D, Carethers JM, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res. 2004 May 01; 64(9):3014-21. PMID: 15126336.
-
Arnold CN, Goel A, Compton C, Marcus V, Niedzwiecki D, Dowell JM, Wasserman L, Inoue T, Mayer RJ, Bertagnolli MM, Boland CR. Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer. Cancer Biol Ther. 2004 Jan; 3(1):73-8. PMID: 14726676.
-
Bertagnolli MM. The potential of non-steroidal anti-inflammatory drugs (NSAIDs) for colorectal cancer prevention. J Surg Oncol. 2003 Nov; 84(3):113-9. PMID: 14598353.
-
Bertagnolli MM. Colorectal cancer prevention studies: the importance of defining disease risk. Ann Surg Oncol. 2003 Oct; 10(8):829-30. PMID: 14527896.
-
Goel A, Arnold CN, Niedzwiecki D, Chang DK, Ricciardiello L, Carethers JM, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR. Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res. 2003 Apr 01; 63(7):1608-14. PMID: 12670912.
-
George S, Hornick JL, Bertagnolli MM, Fletcher CD, Demetri GD. Current management of metastatic gastrointestinal stromal tumor: a case report. Clin Adv Hematol Oncol. 2003 Jan; 1(1):63-4; discussion 65. PMID: 16227963.
-
Carothers AM, Hughes SA, Ortega D, Bertagnolli MM. 2-Methoxyestradiol induces p53-associated apoptosis of colorectal cancer cells. Cancer Lett. 2002 Dec 10; 187(1-2):77-86. PMID: 12359354.
-
Hughes SA, Carothers AM, Hunt DH, Moran AE, Mueller JD, Bertagnolli MM. Adenomatous polyposis coli truncation alters cytoskeletal structure and microtubule stability in early intestinal tumorigenesis. J Gastrointest Surg. 2002 Nov-Dec; 6(6):868-74; discussion 875. PMID: 12504226.
-
Cole DJ, Bertagnolli MM, Nussbaum M. Society of University Surgeons statement on surgical resident work hours and education. Surgery. 2002 Aug; 132(2):115-8. PMID: 12219000.
-
O'Shaughnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, Hong WK, Fabian CJ, Sigman CC, Bertagnolli MM, Stratton SP, Lam S, Nelson WG, Meyskens FL, Alberts DS, Follen M, Rustgi AK, Papadimitrakopoulou V, Scardino PT, Gazdar AF, Wattenberg LW, Sporn MB, Sakr WA, Lippman SM, Von Hoff DD. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res. 2002 Feb; 8(2):314-46. PMID: 11839647.
-
Carothers AM, Melstrom KA, Mueller JD, Weyant MJ, Bertagnolli MM. Progressive changes in adherens junction structure during intestinal adenoma formation in Apc mutant mice. J Biol Chem. 2001 Oct 19; 276(42):39094-102. PMID: 11483600.
-
Weyant MJ, Carothers AM, Mahmoud NN, Bradlow HL, Remotti H, Bilinski RT, Bertagnolli MM. Reciprocal expression of ERalpha and ERbeta is associated with estrogen-mediated modulation of intestinal tumorigenesis. Cancer Res. 2001 Mar 15; 61(6):2547-51. PMID: 11289129.
-
Weyant MJ, Carothers AM, Dannenberg AJ, Bertagnolli MM. (+)-Catechin inhibits intestinal tumor formation and suppresses focal adhesion kinase activation in the min/+ mouse. Cancer Res. 2001 Jan 01; 61(1):118-25. PMID: 11196148.
-
Weisberg NK, Bertagnolli MM, Becker DS. Combined sentinel lymphadenectomy and mohs micrographic surgery for high-risk cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2000 Sep; 43(3):483-8. PMID: 10954660.
-
Mahmoud NN, Carothers AM, Grunberger D, Bilinski RT, Churchill MR, Martucci C, Newmark HL, Bertagnolli MM. Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis. Carcinogenesis. 2000 May; 21(5):921-7. PMID: 10783313.
-
Churchill M, Chadburn A, Bilinski RT, Bertagnolli MM. Inhibition of intestinal tumors by curcumin is associated with changes in the intestinal immune cell profile. J Surg Res. 2000 Apr; 89(2):169-75. PMID: 10729246.
-
Weyant MJ, Carothers AM, Bertagnolli ME, Bertagnolli MM. Colon cancer chemopreventive drugs modulate integrin-mediated signaling pathways. Clin Cancer Res. 2000 Mar; 6(3):949-56. PMID: 10741720.
-
Mahmoud NN, Mack CA, DeCosse JJ, Michaeli J, Bertagnolli MM. Debulking of a gastrointestinal hemangioma alleviates coagulopathy associated with Kasabach-Merritt syndrome. Surgery. 1999 Feb; 125(2):236-8. PMID: 10026761.
-
Mahmoud NN, Dannenberg AJ, Bilinski RT, Mestre JR, Chadburn A, Churchill M, Martucci C, Bertagnolli MM. Administration of an unconjugated bile acid increases duodenal tumors in a murine model of familial adenomatous polyposis. Carcinogenesis. 1999 Feb; 20(2):299-303. PMID: 10069468.
-
Mahmoud NN, Bilinski RT, Churchill MR, Edelmann W, Kucherlapati R, Bertagnolli MM. Genotype-phenotype correlation in murine Apc mutation: differences in enterocyte migration and response to sulindac. Cancer Res. 1999 Jan 15; 59(2):353-9. PMID: 9927046.
-
Bertagnolli MM. Cyclooxygenase-2 as a target for prevention of colorectal cancer. Curr Oncol Rep. 1999; 1(2):173-8. PMID: 11122816.
-
Bertagnolli MM. APC and intestinal carcinogenesis. Insights from animal models. Ann N Y Acad Sci. 1999; 889:32-44. PMID: 10668480.
-
Weyant MJ, Maluccio MA, Bertagnolli MM, Daly JM. Choledochal cysts in adults: a report of two cases and review of the literature. Am J Gastroenterol. 1998 Dec; 93(12):2580-3. PMID: 9860432.
-
Newmark HL, Bertagnolli MM. Aspirin and colon cancer prevention. Gastroenterology. 1998 Oct; 115(4):1036. PMID: 9786735.
-
Mahmoud NN, Dannenberg AJ, Mestre J, Bilinski RT, Churchill MR, Martucci C, Newmark H, Bertagnolli MM. Aspirin prevents tumors in a murine model of familial adenomatous polyposis. Surgery. 1998 Aug; 124(2):225-31. PMID: 9706142.
-
Mahmoud NN, Boolbol SK, Dannenberg AJ, Mestre JR, Bilinski RT, Martucci C, Newmark HL, Chadburn A, Bertagnolli MM. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. Carcinogenesis. 1998 Jan; 19(1):87-91. PMID: 9472698.
-
Mahmoud NN, Boolbol SK, Bilinski RT, Martucci C, Chadburn A, Bertagnolli MM. Apc gene mutation is associated with a dominant-negative effect upon intestinal cell migration. Cancer Res. 1997 Nov 15; 57(22):5045-50. PMID: 9371501.
-
Bertagnolli MM, McDougall CJ, Newmark HL. Colon cancer prevention: intervening in a multistage process. Proc Soc Exp Biol Med. 1997 Nov; 216(2):266-74. PMID: 9349696.
-
Bertagnolli MM, Mahmoud NN, Daly JM. Surgical aspects of colorectal carcinoma. Hematol Oncol Clin North Am. 1997 Aug; 11(4):655-77. PMID: 9257150.
-
Boolbol SK, Dannenberg AJ, Chadburn A, Martucci C, Guo XJ, Ramonetti JT, Abreu-Goris M, Newmark HL, Lipkin ML, DeCosse JJ, Bertagnolli MM. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 1996 Jun 01; 56(11):2556-60. PMID: 8653697.
-
Shyjan AM, Bertagnolli M, Kenney CJ, Briskin MJ. Human mucosal addressin cell adhesion molecule-1 (MAdCAM-1) demonstrates structural and functional similarities to the alpha 4 beta 7-integrin binding domains of murine MAdCAM-1, but extreme divergence of mucin-like sequences. J Immunol. 1996 Apr 15; 156(8):2851-7. PMID: 8609404.
-
Bertagnolli MM, DeCosse JJ. Laparoscopic colon resection for cancer--an unfavorable view. Adv Surg. 1996; 29:155-64. PMID: 8720001.
-
Bertagnolli MM, DeCosse JJ. Laparoscopic colectomy for cancer. J Surg Oncol. 1995 Apr; 58(4):211. PMID: 7723362.
-
Bertagnolli MM, Yang L, Herrmann SH, Kirkman RL. Evidence that rapamycin inhibits interleukin-12-induced proliferation of activated T lymphocytes. Transplantation. 1994 Nov 27; 58(10):1091-6. PMID: 7974715.
-
Andrews JV, Schoof DD, Bertagnolli MM, Peoples GE, Goedegebuure PS, Eberlein TJ. Immunomodulatory effects of interleukin-12 on human tumor-infiltrating lymphocytes. J Immunother Emphasis Tumor Immunol. 1993 Jul; 14(1):1-10. PMID: 8104476.
-
Axford TC, Clair DG, Bertagnolli MM, Mentzer SJ, Sugarbaker DJ. Staged antrectomy and thoracoscopic truncal vagotomy for perforated peptic ulcer disease. Ann Thorac Surg. 1993 Jun; 55(6):1571-3. PMID: 8512418.
-
Bertagnolli MM, Lin BY, Young D, Herrmann SH. IL-12 augments antigen-dependent proliferation of activated T lymphocytes. J Immunol. 1992 Dec 15; 149(12):3778-83. PMID: 1360994.
-
Smith BL, Bertagnolli M, Klein BB, Batter S, Chang M, Douville LM, Eberlein TJ. Evaluation of the contralateral breast. The role of biopsy at the time of treatment of primary breast cancer. Ann Surg. 1992 Jul; 216(1):17-21. PMID: 1321595; PMCID: PMC1242541.
-
Bertagnolli MM, Herrmann SH, Pinto VM, Schoof DD, Eberlein TJ. Approaches to immunotherapy of cancer: characterization of lymphokines as second signals for cytotoxic T-cell generation. Surgery. 1991 Sep; 110(3):459-68. PMID: 1887370.
-
Bertagnolli MM, Takai Y, Herrmann SH. IL-4-supported induction of cytolytic T lymphocytes requires IL-2 and IL-6. Cell Immunol. 1991 Apr 01; 133(2):327-41. PMID: 1901767.
-
Bertagnolli M, Herrmann S. IL-7 supports the generation of cytotoxic T lymphocytes from thymocytes. Multiple lymphokines required for proliferation and cytotoxicity. J Immunol. 1990 Sep 15; 145(6):1706-12. PMID: 2118152.